Beta-adrenergic receptors and reflex tachycardia after single and repeated felodipine administration in essential hypertension
- PMID: 1714023
- DOI: 10.1097/00005344-199106000-00017
Beta-adrenergic receptors and reflex tachycardia after single and repeated felodipine administration in essential hypertension
Abstract
To verify the possible contribution of beta-adrenergic receptor down-regulation to the reversal of reflex tachycardia during chronic treatment with a dihydropyridine calcium antagonist, 11 hypertensive patients were studied with noninvasive blood pressure (BP) and heart rate (HR) monitoring after a placebo period, and on the first and seventh day of felodipine administration, 5 mg twice daily. Plasma catecholamines and neutrophil beta-adrenergic receptors were measured on the first and seventh day of treatment, immediately before and 2 h after drug administration. The first administration of felodipine was followed by a significant drop in BP (peak reduction in mean BP 24 +/- 7 mm Hg), lasting 6 h and mirrored by reflex tachycardia (peak increase in HR 14 +/- 9 beats/min). On the morning of the seventh day, 12 h after the previous felodipine administration, mean BP (MBP) was 16 mm Hg lower than on the last placebo day, while HR was unchanged. The next administration of felodipine was followed by a smaller drop in BP (MBP - 15 +/- 7 mm Hg; NS vs. placebo), while reflex tachycardia was the same as after acute felodipine (HR 13 +/- 8 beats/min; p less than 0.05 vs. placebo, NS vs. acute administration). Plasma noradrenaline concentration increased after both acute and chronic administration (p less than 0.0001), and preadministration values were highest on day 7 (p less than 0.05). Neutrophil beta-adrenergic receptor density and affinity did not change either acutely or chronically. This study gives both indirect and direct evidence that beta-adrenoceptor down-regulation does not occur during repeated felodipine administration in hypertension. Reflex tachycardia is not abolished, but is reset to lower BP levels.
Similar articles
-
Antihypertensive efficacy of the calcium-antagonist felodipine in patients with persisting hypertension on beta-adrenoceptor blocker therapy. The Canadian Felodipine Study Group.Br J Clin Pharmacol. 1988 Nov;26(5):535-45. doi: 10.1111/j.1365-2125.1988.tb05293.x. Br J Clin Pharmacol. 1988. PMID: 2905154 Free PMC article. Clinical Trial.
-
Smooth blood pressure control obtained with extended-release felodipine in elderly patients with hypertension: evaluation by 24-hour ambulatory blood pressure monitoring.Drugs Aging. 2002;19(7):541-51. doi: 10.2165/00002512-200219070-00007. Drugs Aging. 2002. PMID: 12182690 Clinical Trial.
-
Felodipine ER formulation in the treatment of mild hypertension: efficacy and tolerability vs placebo.Br J Clin Pharmacol. 1990 Oct;30(4):567-71. doi: 10.1111/j.1365-2125.1990.tb03814.x. Br J Clin Pharmacol. 1990. PMID: 2291869 Free PMC article. Clinical Trial.
-
Hemodynamic effects of felodipine in hypertension: a review.J Cardiovasc Pharmacol. 1990;15 Suppl 4:S34-9. doi: 10.1097/00005344-199015004-00011. J Cardiovasc Pharmacol. 1990. PMID: 1693723 Review.
-
Dose-plasma concentration--effect relationship of felodipine in essential hypertension: a review.J Cardiovasc Pharmacol. 1990;15 Suppl 4:S50-6. doi: 10.1097/00005344-199015004-00017. J Cardiovasc Pharmacol. 1990. PMID: 1693728 Review.
Cited by
-
Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.Drugs. 1992 Aug;44(2):251-77. doi: 10.2165/00003495-199244020-00008. Drugs. 1992. PMID: 1382018 Review.
-
Amlodipine improves symmetric dimethylarginine in dogs with chronic kidney disease.Front Vet Sci. 2025 Apr 30;12:1570349. doi: 10.3389/fvets.2025.1570349. eCollection 2025. Front Vet Sci. 2025. PMID: 40370820 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous